The European Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for two drugs to prevent COVID-19: Kavigale, a monoclonal antibody, and Kostaive, a self-amplifying mRNA vaccine. Kavigale contains sipavibart, an immunoglobulin that binds to the spike protein of SARS-CoV-2. Kostaive includes zapomeran, a self-replicating mRNA that induces the production of neutralizing antibodies against the virus. Both drugs have shown efficacy in reducing symptomatic COVID-19 in clinical trials. Kavigale is intended for immunocompromised individuals aged 12 or older, while Kostaive is for adults over 18. Common side effects include injection-site reactions. Additional information will be provided upon approval by the European Commission.
Source link
Self-Replicating mRNA Vaccine for COVID Prevention
